EZH2 and hepatocellular carcinoma: The analysis of cooperative genomic alterations of EZH2 using cBioPortal for liver hepatocarcinoma (TCGA, provisional) showed that EZH2 was altered in 11% (39 out of 349) of the HCC patients (Fig 7A).